AHA responds to HRSA's 340B rebate pilot program estimates

The American Hospital Association is urging HRSA to reconsider its #340B Rebate Model Pilot, citing significant administrative and financial burdens for hospitals. In a new letter, AHA highlights concerns that the pilot could create substantial new administrative and financial burdens for hospitals. AHA estimates that millions of additional staff hours and hundreds of millions in costs could be required to implement the rebate model — resources that might otherwise support patient care. https://lnkd.in/e2RhmEdM #340B #HealthcarePolicy #PatientCare #Hospitals #protect340B #pharmacy #IRA #drugpricing Health Resources and Services Administration (HRSAgov), HHS

The federal 340B Drug Pricing Program has allowed hospitals to buy outpatient drugs at discounted rates and invest those savings into free care, community health programs and free immunizations for low-income and uninsured Texans. But a new 340B Rebate Model Pilot Program would require hospitals to pay the wholesale acquisition cost of selected drugs upfront and receive rebates later — undermining decades of cost savings and success in the program. THA opposes the use of any rebate model in 340B. A recent letter to the U.S. Department of Health and Human Services, signed by more than 160 members of Congress, urged HHS to scrap the rebate pilot program, or to “proceed with the utmost caution” if it moves forward. ➡️ 🔗 Read lawmakers’ letter to HHS here: https://ow.ly/uXvV50WZGqT

The Electronic Prescription Service (EPS) is a significant digital innovation in NHS Wales, replacing paper prescriptions with secure, electronic transfers from a GP to a pharmacy. Over 5 million items have now been dispensed via EPS, with more than half of Welsh pharmacies now on board. The rollout continues at pace, improving safety, efficiency, and convenience for patients and healthcare professionals. Learn more about how EPS is transforming how prescriptions are managed in Wales: https://lnkd.in/e-hEPRks #DigitalHealth #EPS #Innovation #CommunityPharmacy #DigitalTransformation #CPSIF Digital Health and Care Wales Jenny Pugh-Jones Laurence J. Tracey Robertson AAH Pharmaceuticals Apotech Boots UK Cegedim @Clanwilliam Community Pharmacy Wales Invatech Health Ltd NHS England NHS Wales Shared Services Partnership Optum PharmacyX Positive Solutions

If you're working in Pharma and want to understand how recent NHS changes are influencing prescribing decisions and medicines optimisation – this Q&A is not to be missed. In this live NHS Whispers Q&A, my colleague, Charlotte Harding (Consultant – Market Access), will be speaking to Yousaf Ahmad (Chief Pharmacist and Director of Medicines Optimisation, Frimley ICS) to explore how pharmacy leaders are responding to NHS restructuring, financial pressures, and evolving priorities – and what this means for industry partners. 📅 Friday 24th October 🕚 11.30am BST/12.30pm CEST 👉https://lnkd.in/exnw-JFS 💬 Expect insights on: • How ICS pharmacy leaders are interpreting NHS restructuring and financial constraints • The role of ICS pharmacy leadership in shaping prescribing, pricing, and access • Confidential pricing arrangements in primary care – and implications for industry • Pharmacist views on the Single National Formulary • What ICS pharmacy teams need to succeed – and how industry can support 📹 Can’t make it live? Register anyway to receive the recording 👉 https://lnkd.in/exnw-JFS Learn more at: https://lnkd.in/ertvymNJ #NHSWhispers #ICSpharmacy #medicinesoptimisation #marketaccess #pharmacyleadership #healthcarestrategy #pharmaengagement #UKhealthcare #medtech #pharma #realworldinsights

If you're working in Pharma and want to understand how recent NHS changes are influencing prescribing decisions and medicines optimisation – this Q&A is not to be missed. In this live NHS Whispers Q&A, my colleague, Charlotte Harding (Consultant – Market Access), will be speaking to Yousaf Ahmad (Chief Pharmacist and Director of Medicines Optimisation, Frimley ICS) to explore how pharmacy leaders are responding to NHS restructuring, financial pressures, and evolving priorities – and what this means for industry partners. 📅 Friday 24th October 🕚 11.30am BST/12.30pm CEST 👉 https://lnkd.in/eXhQz7RA 💬 Expect insights on: • How ICS pharmacy leaders are interpreting NHS restructuring and financial constraints • The role of ICS pharmacy leadership in shaping prescribing, pricing, and access • Confidential pricing arrangements in primary care – and implications for industry • Pharmacist views on the Single National Formulary • What ICS pharmacy teams need to succeed – and how industry can support 📹 Can’t make it live? Register anyway to receive the recording 👉 https://lnkd.in/eXhQz7RA Learn more at: https://lnkd.in/eUKbfw6g #NHSWhispers #ICSpharmacy #medicinesoptimisation #marketaccess #pharmacyleadership #healthcarestrategy #pharmaengagement #UKhealthcare #medtech #pharma #realworldinsights

If you're working in Pharma and want to understand how recent NHS changes are influencing prescribing decisions and medicines optimisation – this Q&A is not to be missed. In this live NHS Whispers Q&A, my colleague, Charlotte Harding (Consultant – Market Access), will be speaking to Yousaf Ahmad (Chief Pharmacist and Director of Medicines Optimisation, Frimley ICS) to explore how pharmacy leaders are responding to NHS restructuring, financial pressures, and evolving priorities – and what this means for industry partners. 📅 Friday 24th October 🕚 11.30am BST/12.30pm CEST 👉 https://lnkd.in/eu2wuJvS 💬 Expect insights on: • How ICS pharmacy leaders are interpreting NHS restructuring and financial constraints • The role of ICS pharmacy leadership in shaping prescribing, pricing, and access • Confidential pricing arrangements in primary care – and implications for industry • Pharmacist views on the Single National Formulary • What ICS pharmacy teams need to succeed – and how industry can support 📹 Can’t make it live? Register anyway to receive the recording 👉 https://lnkd.in/eu2wuJvS Learn more at: https://lnkd.in/eVm-G-Wq #NHSWhispers #ICSpharmacy #medicinesoptimisation #marketaccess #pharmacyleadership #healthcarestrategy #pharmaengagement #UKhealthcare #medtech #pharma #realworldinsights

If you're working in Pharma and want to understand how recent NHS changes are influencing prescribing decisions and medicines optimisation – this Q&A is not to be missed. In this live NHS Whispers Q&A, my colleague, Charlotte Harding (Consultant – Market Access), will be speaking to Yousaf Ahmad (Chief Pharmacist and Director of Medicines Optimisation, Frimley ICS) to explore how pharmacy leaders are responding to NHS restructuring, financial pressures, and evolving priorities – and what this means for industry partners. 📅 Friday 24th October 🕚 11.30am BST/12.30pm CEST 👉 https://lnkd.in/efxuDaff 💬 Expect insights on: • How ICS pharmacy leaders are interpreting NHS restructuring and financial constraints • The role of ICS pharmacy leadership in shaping prescribing, pricing, and access • Confidential pricing arrangements in primary care – and implications for industry • Pharmacist views on the Single National Formulary • What ICS pharmacy teams need to succeed – and how industry can support 📹 Can’t make it live? Register anyway to receive the recording 👉 https://lnkd.in/efxuDaff Learn more at: https://lnkd.in/ehvazbUb #NHSWhispers #ICSpharmacy #medicinesoptimisation #marketaccess #pharmacyleadership #healthcarestrategy #pharmaengagement #UKhealthcare #medtech #pharma #realworldinsights

⚡️The GLP-1 Verification Crisis 41% of UK adults want NHS weight-loss treatments, creating a massive private market opportunity. 🔹The Market Reality: Two-thirds of 25-34 year olds want access despite being "unlikely clinically eligible," while 21% have already attempted to access treatments through pharmacies. NPA warns of ‘spiralling demand’ for NHS weight-loss medications. This creates huge demand for private GLP-1 providers. 📌 Read more: https://bit.ly/4n8nukP 🔹 The Compliance Challenge: 🔻Patient validation: Proving eligibility beyond basic BMI measurements 🔻Treatment monitoring: Demonstrating ongoing medical necessity 🔻Regulatory compliance: Meeting requirements for proper patient assessment 🔻Outcome verification: Showing treatments deliver promised results 🔹 The FitXpress Solution: Mobile body composition verification that helps GLP-1 providers maintain UK compliance: 🔬 Proper patient validation: Body composition data supporting treatment eligibility beyond BMI 📊 Ongoing monitoring compliance: Regular body scans proving continued medical necessity ✅ Treatment verification: Objective evidence showing medications deliver real body composition changes 🎯 Regulatory documentation: Clinical-grade data supporting prescribing decisions and audits 🔹 The Provider Advantage: Stand out from unregulated competitors with proper patient validation. Every consultation becomes a documented, evidence-based decision that demonstrates regulatory compliance and treatment effectiveness. 👉 Ready to enhance your GLP-1 practice with compliant patient validation and outcome verification? Book your FitXpress demo: 📩 https://bit.ly/4iDIz3Y

What You Should Do Now to Prepare for Medicare 2026 Review your current plan: Benefits, premiums, drug coverage, provider network. Because plans change, what’s ideal in 2025 may not be in 2026. Compare options during Open Enrollment (Oct 15 – Dec 7, 2025). Watch for notices in the mail from Medicare or your current plan (they must notify enrollees of changes). Look closely at your drug costs — Part D changes, new negotiated prices, shifting formularies may affect your costs. If you have higher income, check how IRMAA changes will affect your premiums. Plan for higher cost sharing — the increases in premiums, deductibles, and caps mean out-of-pocket costs may rise. Consider timing large prescription fills or procedures before year-end if they could be more expensive under new rules.

This is an issue that if not addressed will have significant impact on long term care access, particularly in rural areas. Institutional pharmacies are a key component to care delivery and if we don’t pass this bill pharmacies will close and once again long term care access will be impacted.